Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;74(9):1559-1565.
doi: 10.1002/acr.24597. Epub 2022 Jun 10.

Antibodies to Both Ro52 and Ro60 for Identifying Sjögren's Syndrome Patients Best Suited for Clinical Trials of Disease-Modifying Therapies

Berkan Armağan  1 , Susan A Robinson  2 , Adriana Bazoberry  2 , Jamie Perin  3 , Thomas Grader-Beck  2 , Esen K Akpek  2 , Jean Kim  2 , Alan N Baer  2
Affiliations

Antibodies to Both Ro52 and Ro60 for Identifying Sjögren's Syndrome Patients Best Suited for Clinical Trials of Disease-Modifying Therapies

Berkan Armağan et al. Arthritis Care Res (Hoboken). 2022 Sep.

Abstract

Objective: To assess anti-Ro52 and anti-Ro60 serologic profiles as markers of clinically relevant phenotypic subsets of patients with Sjögren's syndrome (SS).

Methods: From a cohort of 839 consecutive patients with suspected or established SS seen in our multidisciplinary SS center, we compared the association of key phenotypic features in 390 patients who fulfilled SS classification criteria and in the parent cohort, stratifed by the presence of both anti-Ro60 and anti-Ro52, anti-Ro60 alone, and anti-Ro52 alone.

Results: The SS cohort included 227 patients (58%) with both anti-Ro60 and anti-Ro52, 65 (17%) with anti-Ro60 alone, 58 (15%) with anti-Ro52 alone, and 40 (10%) with neither antibody. Those with both anti-Ro60 and anti-Ro52 had a significantly increased prevalence of abnormal ocular surface staining, focal lymphocytic sialadenitis with focus score ≥1, antinuclear antibody ≥1:320, anti-SSB/La, rheumatoid factor, and IgG ≥15.6 gm/liter (P < 0.0016 for all). The groups with isolated anti-Ro52 and anti-Ro60 were equivalent to each other in their phenotypic associations, except for rheumatoid factor, which was higher in the anti-Ro52 alone group. The associations of these Ro antibody serologic profiles were similar in the parent cohort, except for additional associations with salivary gland enlargement and parotid gland ultrasound score.

Conclusion: SS patients with both anti-Ro60 and anti-Ro52 antibodies are distinguished by a higher prevalence of markers of B-cell hyperactivity and glandular inflammation. Antibody reactivity to both Ro60 and Ro52 may thus serve as an important inclusion criterion for SS patients in clinical trials where the therapeutic agent targets pathways mediating these pathogenic abnormalities.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: Dr. Grader-Beck reports grants from Lilly and Novartis, outside the submitted work.

Dr. Akpek reports grants from WL Gore & Associates, personal fees from Novaliq, Clementia, Regeneron, EpiTech, Sylenitis, Aurinia, and Dompe, and other from CorneaGen., outside the submitted work.

Dr. Kim reports personal fees from ALK and Genentech, outside the submitted work.

Dr. Baer reports personal fees from Bristol-Myers Squibb, AbbVie, Sanofi-Aventis, and Mitsubishi Tanabe Pharma America, outside the submitted work.

Figures

Figure.
Figure.
Prevalence of key phenotypic features in relation to three anti-SSA/Ro serologic profiles (radar plots), shown for the 390 patients with Sjögren’s syndrome (panel A) and the parent cohort of 839 patients with suspected or established Sjögren’s syndrome (panel B). Overall comparisons of the three serologic profile groups showed significant differences with respect to each of these phenotypic features.
See this image and copyright information in PMC

References

    1. Yoshimi R, Ueda A, Ozato K, Ishigatsubo Y. Clinical and pathological roles of Ro/SSA autoantibody system. Clin Dev Immunol 2012;2012:606195. - PMC - PubMed
    1. Boire G, Lopez-Longo FJ, Lapointe S, Menard HA. Sera from patients with autoimmune disease recognize conformational determinants on the 60-kd Ro/SS-A protein. Arthritis Rheum 1991; Jun;34(6):722–30. - PubMed
    1. Scofield RH, Farris AD, Horsfall AC, Harley JB. Fine specificity of the autoimmune response to the Ro/SSA and La/SSB ribonucleoproteins. Arthritis Rheum 1999; Feb;42(2):199–209. - PubMed
    1. Peene I, Meheus L, De Keyser S, Humbel R, Veys EM, De Keyser F. Anti-Ro52 reactivity is an independent and additional serum marker in connective tissue disease. Ann Rheum Dis 2002; Oct;61(10):929–33. - PMC - PubMed
    1. Infantino M, Bentow C, Seaman A, Benucci M, Atzeni F, Sarzi-Puttini P, et al. Highlights on novel technologies for the detection of antibodies to Ro60, Ro52, and SS-B. Clin Dev Immunol 2013;2013:978202. - PMC - PubMed

Publication types

LinkOut - more resources